Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Minute Insight: Sema4 To Acquire Genomics Company GeneDx For $623M To Strengthen Clinical Data Platform

Executive Summary

Genetic testing company Sema4 announced plans to buy GeneDx to strengthen Sema4’s health intelligence and genomic screening offers. The combined company is expected to generate $350m in pro forma 2022 revenue. 

You may also be interested in...



Blank Check Companies’ Hunt For Innovative Medtech Start-Ups To Heat Up Further, Experts Predict

As the SPAC boom continues, innovative medtechs are expected to become acquisition targets.

SVB’s Milo Bissin Predicts ‘Reckoning In 2024’ For Health Care Companies With Sky-High Valuations

VC funding will remain challenging for many in the health care industry, Silicon Valley Bank’s market manager Milo Bissin told attendees at the recent DHIS West conference. Companies focusing on promising areas such as AI-powered technologies, women’s health and value-based care likely have the best chances to draw investors’ attention.

AAOS: Study Finds Robots Do Not Help Knee Revisions; Analysts Bullish On Ortho; More

Studies presented at the American Academy of Orthopedic Surgeons' annual meeting in San Francisco found that robotics did not improve revision rates in total knee arthroplasty surgeries and chatbots do not consistently provide accurate information to orthopedics patients. Wall Street analysts came away from the meeting bullish on the joint reconstruction surgery market. More news from the 12-16 February meeting.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT144957

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel